Evidence mapPaperPMID 42493595Full record

Reviewnpj biomedical innovations2026

Engineering human Gut-on-a-Chip culturomics for predictive pharmacomicrobiomics of first-pass metabolism.

Itsuma Nagao, Hyun Jung Kim

Abstract readReview
In one paragraph

Review in npj biomedical innovations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Itsuma NagaoDepartment of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH, USA.
Hyun Jung KimDepartment of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH, USA. kimh19@ccf.org.

Funding

Japan Society for the Promotion of Science Research Fellowship for Young Scientists 24KJ0651NIH NCI IMAT program 1R33CA286797
6 · The paper itself

Abstract

For orally administered drugs, intestinal first-pass metabolism influences systemic exposure and accounts for inter-individual pharmacokinetic differences. However, the mechanistic roles of gut microbiome-mediated biotransformation and patient-specific intestinal variability remain underrepresented in current regulatory frameworks. This Perspective explores how human-relevant culturomics platforms, including Gut-on-a-Chip microphysiological systems, allow for quantitative analysis of host-microbiome-drug interactions. We also discuss the potential of predictive intestinal ecosystem models for personalized pharmacomicrobiomics and next-generation translational drug development.

Identifiers

PMID42493595
PMCPMC13396778

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.